What short‑term benzodiazepine regimen is appropriate for a patient with worsening anxiety who is receiving Spravato (esketamine)?

Short-Term Benzodiazepine Use for Worsening Anxiety with Spravato

For patients experiencing worsening anxiety while receiving Spravato (esketamine), short-term benzodiazepine therapy is appropriate using a time-limited regimen of 2-6 weeks maximum, with preference for shorter-acting agents like lorazepam 0.5-2 mg as needed or oxazepam 10-30 mg as needed, while ensuring the patient has concurrent optimization of their oral antidepressant and addressing any medical causes of anxiety first.

Clinical Reasoning and Evidence-Based Approach

Primary Considerations

The FDA label for Spravato does not contraindicate benzodiazepine use, and the clinical trials included patients on various concomitant medications 1. Importantly, esketamine itself demonstrates anxiolytic effects - recent meta-analyses show significant reduction in anxiety symptoms in patients with treatment-resistant depression (SMD = -1.23,95% CI: [-1.71, -0.75]) 2, 3. This means the anxiety may improve as Spravato takes effect.

Specific Benzodiazepine Regimen

For acute/episodic anxiety worsening:

• Lorazepam 0.5-2 mg as needed (maximum 2.5 mg/day total)
• Oxazepam 10-30 mg as needed
• Duration: 2-4 weeks maximum during Spravato initiation phase

Rationale: Shorter-acting benzodiazepines are preferred for episodic anxiety and carry lower risk of accumulation and cognitive impairment 4. The guideline explicitly warns that benzodiazepines "should be time limited in accordance with established psychiatric guidelines" due to risks of abuse, dependence, and cognitive impairment 5.

Critical Timing Consideration

Spravato shows most of its antidepressant effect within 24 hours, with continued improvement through Day 28 1. The anxiety reduction follows a similar trajectory 6, 7. This means:

• Benzodiazepines should bridge the first 2-4 weeks while Spravato and the oral antidepressant establish efficacy
• Re-assess anxiety weekly during this period
• Begin tapering benzodiazepines by week 3-4 as Spravato's anxiolytic effects emerge

Essential Pre-Treatment Steps

Before initiating benzodiazepines, the guideline mandates addressing 5:

1. Medical causes of anxiety: Uncontrolled pain, fatigue, infection, electrolyte imbalances, hyperthyroidism, cardiac arrhythmias
2. Delirium screening: Particularly important given esketamine's dissociative properties
3. Medication review: Ensure the newly initiated oral antidepressant (SSRI/SNRI) is optimally dosed - 68% of Spravato trial patients were on SNRIs, 32% on SSRIs 1

Important Caveats and Pitfalls

Avoid these common errors:

• Do not use long-acting benzodiazepines (diazepam, clonazepam) for episodic anxiety - these are for sustained anxiety only 4
• Do not prescribe "as needed indefinitely" - PRN benzodiazepine use paradoxically increases patient preference for continued use, cognitive impairment, and may reduce long-term anxiolytic efficacy 8
• Do not exceed 6 weeks - the guideline is explicit that longer-term use carries "increased risk of abuse and dependence" and "cognitive impairment" 5
• Monitor for dissociation interaction - while not contraindicated, both esketamine and benzodiazepines affect consciousness; ensure 90-minute post-Spravato monitoring is adequate 9

Monitoring and Tapering Protocol

Weekly assessment during weeks 1-4:

• Anxiety severity (use GAD-7 score - target <10)
• Benzodiazepine frequency of use
• Functional impairment
• Compliance with Spravato dosing (twice weekly initially)

Tapering strategy (weeks 3-6):

• If anxiety improving: reduce benzodiazepine dose by 25% weekly
• If anxiety persists: consider increasing Spravato dose from 56mg to 84mg (67% of responders required 84mg by Day 28) 1
• If anxiety worsens despite optimal Spravato dosing: refer for psychotherapy (CBT, exposure therapy) rather than continuing benzodiazepines 5

Alternative Considerations

If benzodiazepines are contraindicated (substance use history, cognitive impairment, elderly with fall risk):

• Hydroxyzine 25-50 mg as needed (non-addictive anxiolytic)
• Gabapentin 300-600 mg TID (off-label but evidence-based for anxiety)
• Immediate psychotherapy referral for CBT or relaxation techniques 5

Evidence Strength Note

The recommendation for time-limited benzodiazepines comes from high-quality guidelines 5, 10, while the specific dosing for episodic anxiety is supported by older but consistent literature 4. The esketamine anxiolytic data is recent (2021-2026) and robust 6, 2, 7, 3, supporting the strategy of brief benzodiazepine bridging while awaiting esketamine's full effect.